Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Longwood Fund
AddedFeb 13, 2024
UpdatedJun 28, 2026
Longwood Fund

Longwood Fund

Operating

Longwood Fund Management: A US-based venture capital firm specializing in healthcare and biotech investments.

Location
Boston, MA, US
Founded
2010
Firm
Compare
Portfolio
Employees
Website

Investments

Tome Biosciences
Tome Biosciences

Total Raised

$213M

Rounds

1

Series A$213MDecember 2023
Solu Therapeutics
Solu Therapeutics

Total Raised

$31M

Rounds

1

Seed$31MAugust 2023
Photys Therapeutics
Photys Therapeutics

Total Raised

$75M

Rounds

1

Series A$75MSeptember 2022
DEM Biopharma
DEM Biopharma

Total Raised

$70M

Rounds

1

Series A$70MJune 2022
Carbon Biosciences
Carbon Biosciences

Total Raised

$38M

Rounds

1

Series A$38MJune 2022
Be Biopharma
Be Biopharma

Total Raised

$182M

Rounds

2

Series B$130MApril 2022
Series A$52MOctober 2020
Rectify Pharmaceuticals
Rectify Pharmaceuticals

Total Raised

$100M

Rounds

1

Series A$100MOctober 2021
Axial Therapeutics
Axial Therapeutics

Total Raised

$110.9M

Rounds

5

Series C$37.3MOctober 2021
Series B$25MFebruary 2019
Immunitas Therapeutics
Immunitas Therapeutics

Total Raised

$97M

Rounds

2

Series B$58MAugust 2021
ImmuneID
ImmuneID

Total Raised

$67M

Rounds

2

Series A$50MJune 2021
Series Unknown$17MFebruary 2021
Interius BioTherapeutics
Interius BioTherapeutics

Total Raised

$103M

Rounds

3

Series A$76MMay 2021
Renovia
Renovia

Total Raised

$72.3M

Rounds

5

Series C$17MApril 2021
Series B$32.3MAugust 2018
XyloCor Therapeutics
XyloCor Therapeutics

Total Raised

$39.6M

Rounds

2

Series A$22.6MMarch 2021
TScan Therapeutics
TScan Therapeutics
Public

Total Raised

$197.5M

Rounds

6

Series C$100MJanuary 2021
Series B$35MJanuary 2020
Series BJuly 2019
Werewolf Therapeutics
Werewolf Therapeutics
Public

Total Raised

$128.2M

Rounds

3

Series B$72MJanuary 2021
Series A$56.2MNovember 2019
Lassen Therapeutics
Lassen Therapeutics

Total Raised

$116M

Rounds

2

Series A$31MJune 2020
Twentyeight-Seven Therapeutics
Twentyeight-Seven Therapeutics

Total Raised

$80M

Rounds

3

Series A$15MMay 2019
Series A$65MSeptember 2018